Zhang Wei/China News Service/VCG via Getty ImagesChinese tech giant Tencent has started a Parkinson’s clinical trial in the U.K. in partnership with London startup Medopad, which has developed a smartphone app that can gather data on patients for doctors to analyze. Tencent and Medopad did not immediately respond to Forbes' request for comment. "Medopad and Tencent are conducting trials to develop and validate algorithms that can potentially predict complications across a range of disease indications like Parkinson’s, cancer and heart diseases," Medopad writes on its website. Like DeepMind, Medopad has signed a number of deals with NHS Trusts including the Royal Free in North London and Royal Wolverhampton. Headquartered in Shenzhen, Tencent owns instant messaging and e-commerce platform WeChat, which boasts over a billion users, as well as several other companies.

Source: Forbes May 07, 2019 11:15 UTC